Table 2.
Study | Anti-VEGF agent | Number of patients | Number of injections |
Percentage (%) of inflammation |
---|---|---|---|---|
Chong et al. (2010) [11] | Bevacizumab | — | 16116 | 0.40% |
Georgopoulos et al. (2009) [25] | Bevacizumab | — | 2500 | 0.03% |
Shima et al. (2008) [16] | Bevacizumab | 707 | 1300 | 0.28% |
Wickremasinghe et al. (2008) [10] | Bevacizumab | — | 1278 | 1.49% |
Johnson et al. (2010) [26] | Bevacizumab | 173 | 693 | 1.30% |
Sato et al. (2010) [22] | Bevacizumab | 35 | 35 | 14.3% |
Yamashiro et al. (2010) [19] | Bevacizumab | 15 | 20 | 73% |
Wang et al. (2013) [24] | Bevacizumab | 116 | 116 | 69% |
Wu et al. (2008) [27] | Bevacizumab | 1173 | 4303 | 0.09% |
Chong et al. (2010) [11] | Ranibizumab | — | 3839 | 0.03% |
Regillo et al. (2008) [28] | Ranibizumab | 184 | — | 0% |
Holz et al. (2011) [29] | Ranibizumab | 514 | — | 0% |
Busbee et al. (2013) [30] | Ranibizumab | 1098 | — | 0.4% |
Rosenfeld et al. (2006) [12] | Ranibizumab | 716 | — | 2.6% |
Brown et al. (2006) [13] | Ranibizumab | 280 | — | 0.35% |
Heier et al. (2006) [31] | Ranibizumab | 105 | — | 11.4% |
Antoszyk et al. (2008) [32] | Ranibizumab | 105 | — | 9.5% |
Rosenfeld et al. (2006) [18] | Ranibizumab | 29 | — | 86% |
Chun et al. (2006) [33] | Ranibizumab | 10 | 30 | 50% |
Chakravarthy et al. (2012) [34] | Bevacizumab and ranibizumab | 610 | — | 0.16% |
Ladas et al. (2009) [35] | Bevacizumab and ranibizumab | 450 | 2000 | 1.90% |
Sharma et al. (2012) [36] | Bevacizumab and ranibizumab | 524 | 1584 | 1.90% |
Hahn et al. (2013) [37] | Aflibercept | — | 30000 | 0.05% |
Ho et al. (2013) [38] | Aflibercept | 85 | — | 0% |
D'Amico et al. (2006) [39] | Pegaptanib | 1190 | — | 0% |
Singerman et al. (2008) [40] | Pegaptanib | 161 | 1254 | 9% |